Treatment | Immunotherapy | Immunotherapy + Chemotherapy | Immunotherapy (c-MET mutation- positive) | c-MET mutations | EFGR mutations | ALK rearrangement | RET mutations |
Chemotherapy (ORR) | PD-1: p = 0.04 PD-L1: p = 0.016 | PD-1: p = 0.0001 PD-L1: p = 0.0002 | PD-1: p = 0.0018 PD-L1: N.A. | p = 0.0005 | p < 0.0001 | p = 0.0001 | p = 0.0001 |
Chemotherapy (PFS) | PD-1: p = 0.02 PD-L1: p = 0.03 | PD-1: p = 0.0012 PD-L1: p = 0.0008 | PD-1: p = 1.15 PD-L1: N.A. | p = 0.0002 | p = 0.0007 | p = 0.0056 | p = 0.04 |
c-MET mutations (ORR) | PD-1: p = 0.12 PD-L1: p = 0.28 | PD-1: p = 0.25 PD-L1: p = 0.47 | N.A | N.A. | N.A. | N.A. | N.A. |
c-MET mutations (PFS) | PD-1: p = 0.66 PD-L1: p = 0.79 | PD-1: p = 0.13 PD-L1: p = 0.34 | N.A | N.A. | N.A | N.A. | N.A. |
Immunotherapy (c-MET mutation- positive) (ORR) | PD-1: p = 0.15 | PD-1: p = 0.01 | N.A. | PD-1: p = 0.07 | N.A. | N.A. | N.A |
Immunotherapy (c-MET mutation- positive) (PFS) | PD-1: p = 0.27 | PD-1: p = 0.07 | N.A. | PD-1: p = 0.07 | N.A. | N.A. | N.A. |